Created at	Source	Raw Value	Validated value
July 12, 2022, 1:30 a.m.	usa	Adverse events (AEs), including solicited AEs and unsolicited AEs;AEs associated with the study intervention;Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody	Adverse events (AEs), including solicited AEs and unsolicited AEs;AEs associated with the study intervention;Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody
July 1, 2022, 11 p.m.	usa	Adverse events (AEs), including solicited AEs and unsolicited AEs;AEs associated with the study intervention;Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of anti-SARS-CoV-2 neutralsing antibody and binding antibody IgGrate (SCR) of anti-SARS-CoV-2 antibody	Adverse events (AEs), including solicited AEs and unsolicited AEs;AEs associated with the study intervention;Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of anti-SARS-CoV-2 neutralsing antibody and binding antibody IgGrate (SCR) of anti-SARS-CoV-2 antibody